公司資料
Assertio 股價、新聞與催化劑
- 股票代碼:
- ASRT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
23.50 USD (+0.13%)
收盤價
最後更新: 2026年6月15日
152M USD
市值
股價為何變動
目前無法取得 ASRT 的收盤價變動背景。
公司概覽
Specialty Pharmaceutical Company
Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care. The company has assembled its portfolio through acquisitions and licensing transactions and operates commercial, market-access, trade, and distribution capabilities.
Rolvedon Oncology Franchise
Rolvedon, or eflapegrastim-xnst, is a long-acting granulocyte colony-stimulating factor used to reduce the incidence of infection manifested by febrile neutropenia in adults receiving myelosuppressive anticancer therapy. It is the company's lead product and is promoted to both hospital systems and community oncology practices.
Sympazan Neurology Product
Sympazan is an oral film formulation of clobazam used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients aged two years and older. The film adheres to the tongue and can serve patients who have difficulty swallowing conventional tablets or liquids.
Hospital and Pain Products
The remaining marketed portfolio includes INDOCIN formulations, SPRIX ketorolac nasal spray, and CAMBIA diclofenac oral solution. These products address hospital, acute-pain, migraine, and inflammatory-care settings, although they are less central to the company's current oncology-focused strategy.
Acquisition-Led Commercial Model
Assertio seeks approved or late-stage products that can be supported through its existing infrastructure. Centralized commercialization and portfolio integration allow the company to manage products across multiple specialty channels without operating a broad internal research platform.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。